More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/Finasteride [98319-26-7]
Chemical Structure
Chemical Structure
Chemical Structure

Finasteride [98319-26-7]

Research Use Only
AG-CR1-3589
AdipoGen Life Sciences
CAS Number98319-26-7
DownloadDatasheet
DownloadMSDS
Product group Chemicals
Estimated Purity>98%
Molecular Weight372.5
Price on request
Packing Size
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    Finasteride [98319-26-7]
  • Delivery Days Customer
    10
  • CAS Number
    98319-26-7
  • Certification
    Research Use Only
  • Estimated Purity
    >98%
  • Hazard Information
    Warning
  • Molecular Formula
    C23H36N2O2
  • Molecular Weight
    372.5
  • Scientific Description
    Chemical. CAS: 98319-26-7. Formula: C23H36N2O2. MW: 372.5. Potent, specific and competitive inhibitor of type II 5alpha-reductase (enzyme which converts testosterone to the more potent 5alpha-dihydrotestosterone). Anticancer compound. Apoptosis modulator. Enhances the action of GABA at GABA(A) receptors, which leads to neurological implications. Inhibit testosterone-induced type I procollagen and TGF-beta1 expression in human scalp dermal fibroblasts in a model of androgenic alopecia. Drug for the treatment of male androgenetic alopecia. Potential role in neuropsychiatric disorders. - Potent, specific and competitive inhibitor of type II 5alpha-reductase (enzyme which converts testosterone to the more potent 5alpha-dihydrotestosterone) [1, 3]. Anticancer compound [2, 6, 7]. Apoptosis modulator [2, 6]. Enhances the action of GABA at GABA(A) receptors, which leads to neurological implications [4]. Inhibit testosterone-induced type I procollagen and TGF-beta1 expression in human scalp dermal fibroblasts in a model of androgenic alopecia [5]. Drug for the treatment of male androgenetic alopecia [8]. Potential role in neuropsychiatric disorders [9]. Shown to reduce L-DOPA-induced dyskinesia in rodent models for Parkinsons disease [10].
  • SMILES
    [H][C@@]12CC[C@H](C(=O)NC(C)(C)C)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])NC(=O)C=C[C@]12C
  • Storage Instruction
    2°C to 8°C
  • UNSPSC
    12352200

References

  • Finasteride: the first 5 alpha-reductase inhibitor: S.L. Sudduth & M.J. Koronkowski; Pharmacotherapy 13, 309 (1993)
  • Induction of apoptosis in rat ventral prostate by finasteride is associated with alteration in MAP kinase pathways and Bcl-2 related family of proteins: H. Huynh; Int. J. Oncol. 20, 1297 (2002)
  • Steroid 5alpha-reductase inhibitors: R. Flores, et al.; Mini Rev. Med. Chem. 3, 225 (2003)
  • A new look at the 5alpha-reductase inhibitor finasteride: D.A. Finn, et al.; CNS Drug Rev. 12, 53 (2006)
  • Perifollicular fibrosis: Pathogenetic role in androgenetic alopecia; H.G. Yoo, et al.; Biol. Pharm. Bull. 29, 1246 (2006)
  • Finasteride induces apoptosis via Bcl-2, Bcl-xL, Bax and caspase-3 proteins in LNCaP human prostate cancer cell line: J.M. Golbano, et al.; Int. J. Oncol. 32, 919 (2008)
  • Molecular profiles of finasteride effects on prostate carcinogenesis: Cancer Prev. Res. 2, 518 (2009)
  • Male androgenetic alopecia: D. Rathnayake & R. Sinclair; Expert Opin. Pharmacother. 11, 1295 (2010)
  • Steroid 5alpha-reductase as a novel therapeutic target for schizophrenia and other neuropsychiatric disorders: S. Paba, et al.; Curr. Pharm. Des. 17, 151 (2011)